Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, Rakesh Popat, William Wilson et al.|The Lancet Haematology|2022Cited by 25
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Kwee Yong, William Wilson et al.|British Journal of Haematology|2021Cited by 15
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).Kwee Yong, Rakesh Popat, Marquita Camilleri et al.|Journal of Clinical Oncology|2021Cited by 5
Upfront Autologous Stem Cell Transplantation (ASCT) vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation with K Maintenance in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Phase 2 Non-Inferiority Cardamon StudyKwee Yong, Rakesh Popat, William Wilson et al.|SSRN Electronic Journal|2022Cited by 0
P-228: ASCT does not benefit patients who are MRD negative following induction therapy: updated results from the Phase 2 Cardamon studyKwee Yong, Rakesh Popat, William W. Wilson et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0